BIRMINGHAM, Ala., February 28, 2023 (Newswire.com) – BioGX, a global provider of easy molecular diagnostic solutions since 2007, has announced fulfillment of multiple initial orders for its portable pixl™ real-time PCR platform to customers across the U.S., with immediate plans to scale production to meet market demand.
“We’re very impressed with the response to the launch of our novel ‘pixl’ qPCR platform. Pixl is accelerating validation and adoption of our vast multiplex RUO syndromic panels available in our unique Xfree and Sample-Ready lyophilized formats,” said Shazi Iqbal, Ph.D., BioGX CEO.
The pixl instrument is a compact, 4-channel, 16-well, real-time-PCR instrument that supports rapid turnaround times for batches of up to 16 samples, with integrated results analysis. Previously, in 2022, the US FDA authorized the pixl platform use with the BioGX Xfree COVID-19 Direct RT-PCR EUA test.
BioGX offers an extensive menu of RUO lyophilized multiplex syndromic panels for laboratory validation on the pixl platform, including the extraction-free Direct-Sample-to-Answer assays: Xfree Human Monkeypox (hMPXV), Xfree HSV1/HSV2/VZV and Xfree Treponema pallidum (Syphilis). The Xfree assay format is compatible with most transport/collection media types and can be validated for a wide variety of clinical sample collections.
View Original Press Release at: